Effect of Two-Stage Goal-Directed Crystalloid versus Colloid Fluid Therapy on Postoperative Quality of Recovery in Patients Undergoing Laparoscopic Hepatectomy: A Randomized Controlled Trial

两阶段目标导向晶体液与胶体液疗法对腹腔镜肝切除术患者术后恢复质量的影响:一项随机对照试验

阅读:1

Abstract

OBJECTIVE: This study aimed to investigate the impact of two-stage goal-directed crystalloid versus colloid fluid therapy on postoperative quality of recovery in patients undergoing laparoscopic hepatectomy. PATIENTS AND METHODS: A total of 116 patients scheduled for elective laparoscopic hepatectomy were randomly assigned to two groups: the goal-directed fluid therapy (GDFT) crystalloid group and the GDFT colloid group. Both groups were monitored for stroke volume variation (SVV) using the FloTrac/Vigileo system, and GDFT was guided based on SVV values. Primary outcome was the 24 h postoperative Quality of Recovery-15 (QoR-15) score. Secondary outcome included the estimated blood loss, lactate levels, total fluid infusion volume, hemodynamic status, postoperative nausea and vomiting (PONV) scores, pain scores, postoperative liver and kidney function, and the incidence of postoperative complications. RESULTS: There was no significant difference in the total QoR-15 scores between the two groups at each point in time (P > 0.05). Compared with the crystalloid group, the colloid group had lower PONV scores at 24 and 48 h postoperatively, fewer times of rescue fluid infusion, and a lower total fluid infusion volume (P < 0.05). Multiple linear regression analysis showed that the estimated blood loss (β = -0.268, P = 0.005) and PONV (β = -0.176, P = 0.045) score were associated with postoperative recovery. CONCLUSION: Two-stage goal-directed crystalloid versus colloid fluid therapy had no significant difference in the postoperative quality of recovery in patients undergoing laparoscopic hepatectomy, which is the primary finding of this study. Nevertheless, our data indicated that colloids may reduce postoperative nausea and vomiting (PONV), though this observation requires confirmation in larger-scale trials.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。